Abstract
A1 68Ga-PSMA PET/CT in staging and restaging of Prostate Cancer Patients: comparative study with 18F-Choline PET/CT
W Langsteger, A Rezaee, W Loidl, HS Geinitz, F Fitz, M Steinmair, G Broinger, L Pallwien-Prettner, M Beheshti
A2 F18 Choline PET – CT: an accurate diagnostic tool for the detection of parathyroid adenoma?
L Imamovic, M Beheshti, G Rendl, D Hackl, O Tsybrovsky, M Steinmair, K Emmanuel, F Moinfar, C Pirich, W Langsteger
A3 [18F]Fluoro-DOPA-PET/CT in the primary diagnosis of medullary thyroid carcinoma
A Bytyqi, G Karanikas, M Mayerhöfer, O Koperek, B Niederle, M Hartenbach
A4 Variations of clinical PET/MR operations: An international survey on the clinical utilization of PET/MRI
T Beyer, K Herrmann, J Czernin
A5 Standard Dixon-based attenuation correction in combined PET/MRI: Reproducibility and the possibility of Lean body mass estimation
I Rausch, P Rust, MD DiFranco, M Lassen, A Stadlbauer, ME Mayerhöfer, M Hartenbach, M Hacker, T Beyer
A6 High resolution digital FDG PET/MRI imaging for assessment of ACL graft viability
K Binzel, R Magnussen, W Wei, MU Knopp, DC Flanigan, C Kaeding, MV Knopp
A7 Using pre-existing hematotoxicity as predictor for severe side effects and number of treatment cycles of Xofigo therapy
A Leisser, M Nejabat, M Hartenbach, G Kramer, M Krainer, M Hacker, A Haug
A8 QDOSE – comprehensive software solution for internal dose assessment
Wencke Lehnert, Karl Schmidt, Sharok Kimiaei, Marcus Bronzel, Andreas Kluge
A9 Clinical impact of Time-of-Flight on next-generation digital PET imaging of Yttrium-90 radioactivity following liver radioembolization
CL Wright, K Binzel, J Zhang, Evan Wuthrick, Piotr Maniawski, MV Knopp
A10 Snakes in patients! Lessons learned from programming active contours for automated organ segmentation
M Blaickner, E Rados, A Huber, M Dulovits, H Kulkarni, S Wiessalla, C Schuchardt, RP Baum, B Knäusl, D Georg
A11 Influence of a genetic polymorphism on brain uptake of the dual ABCB1/ABCG2 substrate [11C]tariquidar
M Bauer, B Wulkersdorfer, W Wadsak, C Philippe, H Haslacher, M Zeitlinger, O Langer
A12 Outcome prediction of temporal lobe epilepsy surgery from P-glycoprotein activity. Pooled analysis of (R)-[11C]-verapamil PET data from two European centres
M Bauer, M Feldmann, R Karch, W Wadsak, M Zeitlinger, MJ Koepp, M-C Asselin, E Pataraia, O Langer
A13 In-vitro and in-vivo characterization of [18F]FE@SNAP and derivatives for the visualization of the melanin concentrating hormone receptor 1
M Zeilinger, C Philippe, M Dumanic, F Pichler, J Pilz, M Hacker, W Wadsak, M Mitterhauser
A14 Reducing time in quality control leads to higher specific radioactivity of short-lived radiotracers
L Nics, B Steiner, M Hacker, M Mitterhauser, W Wadsak
A15 In vitro 11C-erlotinib binding experiments in cancer cell lines with epidermal growth factor receptor mutations
A Traxl, Thomas Wanek, Kushtrim Kryeziu, Severin Mairinger, Johann Stanek, Walter Berger, Claudia Kuntner, Oliver Langer
A16 7-[11C]methyl-6-bromopurine, a PET tracer to measure brain Mrp1 function: radiosynthesis and first PET evaluation in mice
S Mairinger, T Wanek, A Traxl, M Krohn, J Stanek, T Filip, M Sauberer, C Kuntner, J Pahnke, O Langer
A17 18F labeled azidoglucose derivatives as “click” agents for pretargeted PET imaging
D Svatunek, C Denk, M Wilkovitsch, T Wanek, T Filip, C Kuntner-Hannes, J Fröhlich, H Mikula
A18 Bioorthogonal tools for PET imaging: development of radiolabeled 1,2,4,5-Tetrazines
C Denk, D Svatunek, T Wanek, S Mairinger, J Stanek, T Filip, J Fröhlich, H Mikula, C Kuntner-Hannes
A19 Preclinical evaluation of [18F]FE@SUPPY- a new PET-tracer for oncology
T Balber, J Singer, J Fazekas, C Rami-Mark, N Berroterán-Infante, E Jensen-Jarolim, W Wadsak, M Hacker, H Viernstein, M Mitterhauser
A20 Investigation of Small [18F]-Fluoroalkylazides for Rapid Radiolabeling and In Vivo Click Chemistry
C Denk, D Svatunek, B Sohr, H Mikula, J Fröhlich, T Wanek, C Kuntner-Hannes, T Filip
A21 Microfluidic 68Ga-radiolabeling of PSMA-HBED-CC using a flow-through reactor
S Pfaff, C Philippe, M Mitterhauser, M Hartenbach, M Hacker, W Wadsak
A22 Influence of 24-nor-ursodeoxycholic acid on hepatic disposition of [18F]ciprofloxacin measured with positron emission tomography
T Wanek, E Halilbasic, M Visentin, S Mairinger, B Stieger, C Kuntner, M Trauner, O Langer
A23 Automated 18F-flumazenil production using chemically resistant disposable cassettes
P Lam, M Aistleitner, R Eichinger, C Artner
A24 Similarities and differences in the synthesis and quality control of 177Lu-DOTA-TATE, 177Lu -HA-DOTA-TATE and 177Lu-DOTA-PSMA (PSMA-617)
H Eidherr, C Vraka, A Haug, M Mitterhauser, L Nics, M Hartenbach, M Hacker, W Wadsak
A25 68Ga- and 177Lu-labelling of PSMA-617
H Kvaternik, R Müller, D Hausberger, C Zink, RM Aigner
A26 Radiolabelling of liposomes with 67Ga and biodistribution studies after administration by an aerosol inhalation system
U Cossío, M Asensio, A Montes, S Akhtar, Y te Welscher, R van Nostrum, V Gómez-Vallejo, J Llop
A27 Fully automated quantification of DaTscan SPECT: Integration of age and gender differences
F VandeVyver, T Barclay, N Lippens, M Troch
A28 Lesion-to-background ratio in co-registered 18F-FET PET/MR imaging – is it a valuable tool to differentiate between low grade and high grade brain tumor?
L Hehenwarter, B Egger, J Holzmannhofer, M Rodrigues-Radischat, C Pirich
A29 [11C]-methionine PET in gliomas - a retrospective data analysis of 166 patients
N Pötsch, I Rausch, D Wilhelm, M Weber, J Furtner, G Karanikas, A Wöhrer, M Mitterhauser, M Hacker, T Traub-Weidinger
A30 18F-Fluorocholine versus 18F-Fluorodeoxyglucose for PET/CT imaging in patients with relapsed or progressive multiple myeloma: a pilot study
T Cassou-Mounat, S Balogova, V Nataf, M Calzada, V Huchet, K Kerrou, J-Y Devaux, M Mohty, L Garderet, J-N Talbot
A31 Prognostic benefit of additional SPECT/CT in sentinel lymph node mapping of breast cancer patients
S Stanzel, G Pregartner, T Schwarz, V Bjelic-Radisic, B Liegl-Atzwanger, R Aigner
A32 Evaluation of diagnostic value of TOF-18F-FDG PET/CT in patients with suspected pancreatic cancer
S Stanzel, F Quehenberger, RM Aigner
A33 New quantification method for diagnosis of primary hyperpatahyroidism lesions and differential diagnosis vs thyropid nodular disease in dynamic scintigraphy
A Koljević Marković, Milica Janković, V Miler Jerković, M Paskaš, G Pupić, R Džodić, D Popović
A34 A rare case of diffuse pancreatic involvement in patient with merkel cell carcinoma detected by 18F-FDG
MC Fornito, D Familiari
A35 TSH-stimulated 18F-FDG PET/CT in the diagnosis of recurrent/metastatic radioiodine-negative differentiated thyroid carcinomas in patients with various thyroglobuline levels
P Koranda, H Polzerová, I Metelková, L Henzlová, R Formánek, E Buriánková, M Kamínek
A36 Breast Dose from lactation following I131 treatment
WH Thomson, C Lewis
A37 A new concept for performing SeHCAT studies with the gamma camera
WH Thomson, J O’Brien, G James, A Notghi
A38 Whole body F-18-FDG-PET and tuberculosis: sensitivity compared to x-ray-CT
H Huber, I Stelzmüller, R Wunn, M Mandl, F Fellner, B Lamprecht, M Gabriel
A39 Emerging role 18F-FDG PET-CT in the diagnosis and follow-up of the infection in heartware ventricular assist system (HVAD)
MC Fornito, G Leonardi
A40 Validation of Poisson resampling software
WH Thomson, J O’Brien, G James
A41 Protection of PET nuclear medicine personnel: problems in satisfying dose limit requirements
J Hudzietzová, J Sabol, M Fülöp
Collapse